COVID-19 疫苗在孕妇中的接种意愿和犹豫原因：一项多中心横断面调查。

COVID-19 vaccine acceptance among pregnant women and the reasons for hesitancy: A multi-centre cross-sectional survey.

机构信息

Department of Obstetrics & Gynaecology, Westmead Hospital, Sydney, New South Wales, Australia.

Reproduction and Perinatal Centre, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.

出版信息

Aust N Z J Obstet Gynaecol. 2023 Jun;63(3):335-343. doi: 10.1111/ajo.13622. Epub 2022 Oct 19.

DOI:10.1111/ajo.13622

PMID:36259472

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9874455/

Abstract

BACKGROUND

On 9 June 2021, the Australian Technical Advisory Group on Immunisation and Royal Australian and New Zealand College of Obstetricians and Gynaecologists recommended that pregnant women receive Comirnaty (Pfizer) messenger RNA vaccine at any stage of pregnancy.

AIM

This multi-centre study aimed to assess vaccine acceptance, reasons for hesitancy and determine if differences exist between health districts, to inform future policy strategies for COVID-19 vaccination in pregnancy.

MATERIALS AND METHODS

An online survey (developed based on the World Health Organization Behavioural and Social Drivers survey and modified for the pregnant population) was administered to a sample population of pregnant women attending antenatal clinics at two metropolitan hospitals (Westmead and Royal North Shore Hospital (RNSH)) in New South Wales between 15 September 2021 and 22 October 2021.

RESULTS

There were 287 pregnant women surveyed (Westmead 198 (69%), RNSH 66 (23%), no site 23 (8%)). There was a significantly lower Socio-Economic Indexes for Areas score (5.66 vs 9.45, P = 0.001), fewer women born in Australia (37% vs 53%, P = 0.02) and higher number of children (0.77 vs 0.41, P = 0.01) among Westmead respondents. There was lower vaccination uptake (68% vs 86%, P = 0.01) and willingness to receive vaccine (68% vs 88% P = 0.01) at Westmead compared to RNSH. There was an increased proportion of respondents who were concerned that the vaccine could cause harm to the unborn baby at Westmead (38% vs 11%, P = 0.01).

CONCLUSIONS

Along with healthcare provider recommendation for vaccination in pregnancy, materials should be targeted to specific safety concerns of pregnant women.

摘要

背景

2021 年 6 月 9 日，澳大利亚免疫技术咨询小组和澳大利亚皇家妇产科学院建议孕妇在妊娠的任何阶段均可接种 Comirnaty（辉瑞）信使 RNA 疫苗。

目的

本多中心研究旨在评估疫苗接种的接受程度、犹豫的原因，并确定不同卫生区之间是否存在差异，以为妊娠期间 COVID-19 疫苗接种的未来政策策略提供信息。

材料和方法

2021 年 9 月 15 日至 10 月 22 日，我们对在新南威尔士州两家都市医院（韦斯特米德和皇家北岸医院（RNSH））接受产前检查的孕妇样本人群进行了一项在线调查（根据世界卫生组织行为和社会驱动因素调查制定，并针对孕妇人群进行了修改）。

结果

共调查了 287 名孕妇（韦斯特米德 198 名（69%），RNSH 66 名（23%），无地点 23 名（8%））。韦斯特米德的社会经济指数得分显著较低（5.66 对 9.45，P=0.001），出生于澳大利亚的女性较少（37%对 53%，P=0.02），子女较多（0.77 对 0.41，P=0.01）。与 RNSH 相比，韦斯特米德的疫苗接种率较低（68%对 86%，P=0.01），愿意接种疫苗的比例较低（68%对 88%，P=0.01）。在韦斯特米德，有更多的受访者担心疫苗会对胎儿造成伤害（38%对 11%，P=0.01）。